Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform

Key Points

• Tilray Brands generated record first-quarter revenue as BrewDog helped drive an 82% increase in beverage sales.
• International medical cannabis remains a key growth engine, with international cannabis revenue rising 21% and European production costs falling.
• U.S. cannabis reform remains a potential catalyst, but Tilray Brands’ current growth strategy increasingly depends on businesses it already operates.

When investors hear talk of U.S. cannabis reform, they often look at major Canadian operators. Tilray Brands NASDAQ: TLRY frequently finds itself at the center of this conversation. As rumors of Schedule III reclassification circulate, the market tends to price Tilray Brands based on the political winds in Washington. A closer look at the actual revenue engine tells a completely different story.

Right now, Tilray Brands generates no reported U.S. cannabis revenue. Its domestic footprint is built primarily around craft beer, spirits, hospitality, and hemp-based products. Treating the company as a pure-play bet on federal rescheduling ignores the physical operations currently driving Tilray's balance sheet.

The real test for Tilray relies on its ability to scale international medical cannabis and consolidate the beverage alcohol sector. The data, released with the company's first-quarter fiscal 2027 earnings, reveal an enterprise actively prioritizing structural efficiency over speculative domestic catalysts.

Brewing Up Profits Without Congress

Tilray Brands' operations in the United States function far outside the dispensary model. The domestic strategy relies heavily on scaling craft beer, spirits, and hemp-based wellness products through its Manitoba Harvest brand. While the broader market waits for the Drug Enforcement Administration to finalize its stance on medical marijuana, Tilray Brands is executing a calculated roll-up of the beverage alcohol space.

First-quarter results highlight the pivot's effectiveness. Beverage revenue rose roughly 82% year over year to about $101.5 million, nearly doubling the global cannabis segment's output. The recent integration of BrewDog drove much of this growth.

Management acquired the brand, stabilized its operations, and restructured parts of the business. This aggressive restructuring helped the asset become profitable in its first quarter under Tilray Brands. The brand now self-finances, shielding Tilray Brands from the typical cash drag of large-scale integrations.

This focus on capital efficiency pushed overall beverage gross margins to around 41%, up from about 38% a year earlier. The operational scale continues to grow, anchored by an exclusive multi-year agreement to produce and distribute Carlsberg brands across the U.S. starting in January 2027.

By leveraging its existing brewing infrastructure to support globally recognized labels, Tilray Brands expects immediate revenue contributions and higher manufacturing utilization. Tilray Brands is building a self-sustaining domestic revenue base that does not require federal cannabis reform to thrive.

Harvesting High-Margin European Growth

The international medical market represents the primary growth engine for the cannabis portfolio. The recent quarter saw Europe, the Middle East, and Africa revenue climb about 71%, while international cannabis revenue rose about 21% year over year. Operations in Germany and the United Kingdom are expanding, backed by a highly optimized supply chain and direct-to-patient access networks.

The Portuguese cultivation facility anchors this European presence. Management reported an approximately 110% year-over-year increase in EU-GMP certified flower shipments and a 150% jump in oil volumes. By reducing cultivation costs at the Cantanhede site by nearly 40% and improving strain yields, Tilray Brands is strengthening its distinct low-cost production advantage in high-barrier medical markets.

In contrast, domestic Canadian adult-use revenue contracted slightly. Rather than chasing unprofitable market share in an oversaturated environment burdened by heavy excise taxes, management deliberately redirected roughly one metric ton of inventory away from Canadian recreational channels.

Management sent this supply to higher-margin international medical markets. Prioritizing margin over pure volume is a difficult but necessary discipline in legacy markets. This strategic allocation of supply, paired with a transition to higher-yielding cultivars, directly influenced profitability. Total cannabis gross margins expanded 300 basis points to approximately 39%, helping offset about $8.8 million in international price compression.

Liquid Assets in a Drying Sector

The global cannabis industry is entering a period of forced consolidation. Capital constraints and punitive tax structures are pushing operators to merge or acquire distressed assets at steep discounts. The hostile $5-per-share bid from Curaleaf Holdings OTC: CURLF for Aurora Cannabis NASDAQ: ACB clearly signals the prevailing environment. Multi-state operators are actively looking to expand their international infrastructure to prepare for potential 280E tax relief under Schedule III.

In this climate, liquidity and balance sheet stabilization provide a distinct competitive edge. Tilray Brands ended the first quarter holding approximately $221 million in cash and marketable securities. Over the calendar year, Tilray Brands retired roughly $42 million in outstanding debt, deliberately reducing its net cash interest expense. These moves provide the flexibility needed to navigate macroeconomic headwinds, such as elevated global fuel surcharges and supply chain inflation, while limiting the need to rely on additional equity financing.

The underlying business fundamentals remain intact. Management reaffirmed its full-year adjusted EBITDA target of approximately $68 million to $75 million, pointing to expected improvements in cultivation yields and sustained cost controls as the fiscal year progresses.

A High-Conviction Recipe for Investors

As the year unfolds, the market will likely continue to react to political developments around cannabis reform. For investors evaluating the cannabis sector, separating operational execution from regulatory speculation is a useful exercise. Tilray Brands' ability to expand consolidated gross margins to about 30% and deliver immediate profitability in newly acquired segments indicates a maturing operational model.

The current trading price of around $3.50 reflects widespread skepticism and heavy short positioning among institutional traders. Yet, the internal metrics suggest a foundation built on global beverage distribution and international medical supply.

By focusing on variables it can control, reducing unit costs, integrating acquisitions efficiently, and optimizing inventory allocation, Tilray Brands has created a path forward that is not dependent on broader U.S. marijuana rescheduling.